EFFICACY AND SAFETY OF USTEKINUMAB FOR CROHN'S DISEASE THROUGH 5 YEARS: FINAL RESULTS FROM THE IM-UNITI LONG-TERM EXTENSION

William Sandborn  ¹     Paul Rutgeerts  ²     John Lynch  ³     Rory Rebuck  ³     Yuhua Wang  ³     Bin Zou  ³     Christopher Gasink  ⁴     Omoniyi J. Adedokun  ⁴     Bruce E. Sands  ⁵     Stephen B Hanauer  ⁶     Stephan Targan  ⁷     Subrata Ghosh  ⁸     Willem de Villiers  ⁹     Jean-Frédéric Colombel  ¹⁰     Brian G. Feagan  ^11    
1 University of California San Diego, La Jolla, United States
² Katholieke Univeriteit Leuven Dept. of Gastroenterology, Leuven, Belgium
³ Janssen Research & Development, LLC, Spring House, United States
⁴ Janssen Scientific Affairs, LLC, Horsham, United States
⁵ Icahn School of Medicine at Mount Sinai, New York, United States
⁶ Feinberg School of Medicine, Northwestern University, Chicago, United States
⁷ Cedars-Sinai Medical Center, Los Angeles, United States
⁸ Institute of Translational Medicine, Birmingham, United Kingdom
⁹ University of Stellenbosch, Stellenbosch, South Africa
¹⁰ Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, United States
¹¹ Robarts Clinical Trials Inc., London, Canada

Topic
IBD

Session
IBD: Clinical trials II

Conference
UEG Week Virtual 2020

Citation
United European Gastroenterology Journal 2020; 8 (Supplement 1)